Andrew Samy, Ahmed Abd El Aleem, Ahmed Abu-El Hassan
{"title":"Maternal and Fetal Outcomes with Metformin Therapy for Obese Pregnant Women A Randomized Control Trial","authors":"Andrew Samy, Ahmed Abd El Aleem, Ahmed Abu-El Hassan","doi":"10.21608/ebwhj.2023.196608.1238","DOIUrl":null,"url":null,"abstract":"Aim of Work: To investigate the maternal and neonatal outcomes after using metformin among obese non diabetic Egyptian women. Study design: A case control, open label randomized controlled trial. Methods: A case control, open label randomized controlled trial study was conducted on 178 pregnant – 11 to 16 weeks – obese (Body mass index ≥ 30 kg/m 2 ) non diabetic females. Our populations` cohort were equally randomized into 2 groups, cases – who were subjected to receive metformin from the date of recruitment till termination of pregnancy – and controls – who received nothing – with follow up of the maternal glucose levels and documenting the maternal and fetal outcomes. Results: Metformin appeared to have a good patient acceptability with a less weight gain during enrollment of the trial among the pregnant females with a better glycemic control. There is no difference between the 2 groups regarding incidence of developing GDM, gestational hypertension and fetal macrosomia. Conclusion: Using metformin for obese non diabetic females, from the second trimester of pregnancy can reduce the maternal weight gain during pregnancy and provide a better glycemic control with no increase in perinatal and maternal complications.","PeriodicalId":12080,"journal":{"name":"Evidence Based Women's Health Journal","volume":"23 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Women's Health Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/ebwhj.2023.196608.1238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aim of Work: To investigate the maternal and neonatal outcomes after using metformin among obese non diabetic Egyptian women. Study design: A case control, open label randomized controlled trial. Methods: A case control, open label randomized controlled trial study was conducted on 178 pregnant – 11 to 16 weeks – obese (Body mass index ≥ 30 kg/m 2 ) non diabetic females. Our populations` cohort were equally randomized into 2 groups, cases – who were subjected to receive metformin from the date of recruitment till termination of pregnancy – and controls – who received nothing – with follow up of the maternal glucose levels and documenting the maternal and fetal outcomes. Results: Metformin appeared to have a good patient acceptability with a less weight gain during enrollment of the trial among the pregnant females with a better glycemic control. There is no difference between the 2 groups regarding incidence of developing GDM, gestational hypertension and fetal macrosomia. Conclusion: Using metformin for obese non diabetic females, from the second trimester of pregnancy can reduce the maternal weight gain during pregnancy and provide a better glycemic control with no increase in perinatal and maternal complications.